Covidien plc (COV) Announces Publication of Final Results of Pipeline Embolization Device Pivotal Study
6/17/2013 9:36:31 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the final results of the PUFs (Pipeline for Uncoilable or Failed Aneurysms) clinical study of its Pipeline™ embolization device have been published in the June issue of Radiology.1 Radiology is the official peer-reviewed medical journal of the Radiological Society of North America. The Pipeline device met the trial’s primary endpoints for both effectiveness and safety. Based on these data, the Pipeline device was approved by the U.S. Food and Drug Administration (FDA) on April 6, 2011.
Help employers find you! Check out all the jobs and post your resume.
comments powered by